Top

Published in:

01-09-2009 | Preclinical Study

TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro

Authors: Rebecca L. H. Bigelow, Briana J. Williams, Jennifer L. Carroll, Lisa K. Daves, James A. Cardelli

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Abstract

TIMP-1 (Tissue inhibitor of matrix metalloproteinase-1) is typically associated with inhibition of matrix metalloproteinases (MMP) induced invasion. However, TIMP-1 is overexpressed in many malignancies and is associated with poor prognosis in breast cancer. The mechanisms by which TIMP-1 promotes tumorigenesis are unclear. Reduced levels of TIMP-1 mediated by shRNA in MDA-MB-231 breast cancer cells had no effect on cellular physiology in vitro or tumor growth in SCID mice compared to vector control MDA-MB-231 cells. However, overexpression of TIMP-1 in MDA-MB-231 cells resulted in inhibition of cell invasion and enhanced phosphorylation of p38 MAPK and AKT in vitro. Additionally, treatment of parental MDA-MB-231 cells with purified TIMP-1 protein led to activation of p38 MAPK and MKK 3/6. cDNA array analysis demonstrated that high expression of TIMP-1 in MDA-MB-231 cells resulted in alterations in expression of approximately 200 genes, 1.5 fold or greater compared to vector control cells (P < 0.1). Real-time RT-PCR confirmed changes in expression of several genes associated with cancer progression including DAPK1, FGFR4 and MAPK13. In vivo, high TIMP-1 expression induced tumor growth in SCID mice compared to vector control cells and increased tumor vessel density. Affymetrix array analysis of vector control and TIMP-1 MDA-MB-231 xenograft tumors revealed that TIMP-1 altered expression of approximately 600 genes in vivo, including MMP1, MMP13, S100A14, S100P, Rab25 and ID4. These combined observations suggest that the effects of TIMP-1 differ significantly in a 2-D environment compared to the 3-D environment and that TIMP-1 stimulates tumor growth.

Available only for authorised users

Guedez L, McMarlin AJ, Kingma DW, Bennett TA, Stetler-Stevenson M, Stetler-Stevenson WG (2001) Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt’s lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 158:1207–1215PubMed

Kong Y, Poon R, Nadesan P, Di Muccio T, Fodde R, Khokha R et al (2004) Matrix metalloproteinase activity modulates tumor size, cell motility, and cell invasiveness in murine aggressive fibromatosis. Cancer Res 64:5795–5803. doi:10.1158/0008-5472.CAN-03-3112 PubMedCrossRef

Rigg AS, Lemoine NR (2001) Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Ther 8:869–878. doi:10.1038/sj.cgt.7700387 PubMedCrossRef

Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G et al (1989) Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 243:947–950. doi:10.1126/science.2465572 PubMedCrossRef

Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174. doi:10.1038/nrc745 PubMedCrossRef

McCarthy K, Maguire T, McGreal G, McDermott E, O’Higgins N, Duffy MJ (1999) High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 84:44–48. doi :10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.0.CO;2-PPubMedCrossRef

Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O (1997) High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 3:1623–1628PubMed

Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P et al (2002) Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 197:307–313. doi:10.1002/path.1129 PubMedCrossRef

Schrohl AS, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G et al (2003) Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics 2:164–172. doi:10.1074/mcp.M300019-MCP200 PubMedCrossRef

10.

Jiang Y, Goldberg ID, Shi YE (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21:2245–2252. doi:10.1038/sj.onc.1205291 PubMedCrossRef

11.

Wurtz SO, Schrohl AS, Sorensen NM, Lademann U, Christensen IJ, Mouridsen H et al (2005) Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 12:215–227. doi:10.1677/erc.1.00719 PubMedCrossRef

12.

Gasson JC, Golde DW, Kaufman SE, Westbrook CA, Hewick RM, Kaufman RJ et al (1985) Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature 315:768–771. doi:10.1038/315768a0 PubMedCrossRef

13.

Bertaux B, Hornebeck W, Eisen AZ, Dubertret L (1991) Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 97:679–685. doi:10.1111/1523-1747.ep12483956 PubMedCrossRef

14.

Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K (1992) Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298:29–32. doi:10.1016/0014-5793(92)80015-9 PubMedCrossRef

15.

Porter JF, Shen S, Denhardt DT (2004) Tissue inhibitor of metalloproteinase-1 stimulates proliferation of human cancer cells by inhibiting a metalloproteinase. Br J Cancer 90:463–470. doi:10.1038/sj.bjc.6601533 PubMedCrossRef

16.

Taube ME, Liu XW, Fridman R, Kim HR (2006) TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein. Oncogene 25:3041–3048. doi:10.1038/sj.onc.1209336 PubMedCrossRef

17.

Yoshiji H, Harris SR, Raso E, Gomez DE, Lindsay CK, Shibuya M et al (1998) Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 75:81–87. doi :10.1002/(SICI)1097-0215(19980105)75:1<81::AID-IJC13>3.0.CO;2-GPubMedCrossRef

18.

Akahane T, Akahane M, Shah A, Connor CM, Thorgeirsson UP (2004) TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp Cell Res 301:158–167. doi:10.1016/j.yexcr.2004.08.002 PubMedCrossRef

19.

Lafleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR (2002) Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci 115:3427–3438PubMed

20.

Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL (1995) Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 177:275–283. doi:10.1002/path.1711770310 PubMedCrossRef

21.

Hansen S, Sorensen FB, Vach W, Grabau DA, Bak M, Rose C (2004) Microvessel density compared with the Chalkley count in a prognostic study of angiogenesis in breast cancer patients. Histopathology 44:428–436. doi:10.1111/j.1365-2559.2004.01848.x PubMedCrossRef

22.

Liu XW, Bernardo MM, Fridman R, Kim HR (2003) Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 278:40364–40372. doi:10.1074/jbc.M302999200 PubMedCrossRef

23.

Pramanik R, Qi X, Borowicz S, Choubey D, Schultz RM, Han J et al. (2003). p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun. The determinant roles of the isoforms in the p38 MAPK signal specificity. J Biol Chem 278:4831–4839. doi:10.1074/jbc.M207732200

24.

Porter JF, Sharma S, Wilson DL, Kappil MA, Hart RP, Denhardt DT (2005) Tissue inhibitor of metalloproteinases-1 stimulates gene expression in MDA-MB-435 human breast cancer cells by means of its ability to inhibit metalloproteinases. Breast Cancer Res Treat 94:185–193. doi:10.1007/s10549-005-7728-4 PubMedCrossRef

25.

Bialik S, Kimchi A (2004) DAP-kinase as a target for drug design in cancer and diseases associated with accelerated cell death. Semin Cancer Biol 14:283–294. doi:10.1016/j.semcancer.2004.04.008 PubMedCrossRef

26.

Jaakkola S, Salmikangas P, Nylund S, Partanen J, Armstrong E, Pyrhonen S et al (1993) Amplification of fgfr4 gene in human breast and gynecological cancers. Int J Cancer 54:378–382. doi:10.1002/ijc.2910540305 PubMedCrossRef

27.

Johnston CL, Cox HC, Gomm JJ, Coombes RC (1995) bFGF and aFGF induce membrane ruffling in breast cancer cells but not in normal breast epithelial cells: FGFR-4 involvement. Biochem J 306(Pt 2):609–616PubMed

28.

Koziczak M, Hynes NE (2004) Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation. J Biol Chem 279:50004–50011. doi:10.1074/jbc.M404252200 PubMedCrossRef

29.

Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25:9–34. doi:10.1007/s10555-006-7886-9 PubMedCrossRef

30.

Yan C, Boyd DD (2007) Regulation of matrix metalloproteinase gene expression. J Cell Physiol 211:19–26. doi:10.1002/jcp.20948 PubMedCrossRef

31.

Feltes CM, Kudo A, Blaschuk O, Byers SW (2002) An alternatively spliced cadherin−11 enhances human breast cancer cell invasion. Cancer Res 62:6688–6697PubMed

32.

Kondo S, Lu Y, Debbas M, Lin AW, Sarosi I, Itie A et al (2003) Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). Proc Natl Acad Sci USA 100:5431–5436. doi:10.1073/pnas.0530308100 PubMedCrossRef

33.

Sharma G, Mirza S, Prasad CP, Srivastava A, Gupta SD, Ralhan R (2007) Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci 80:1873–1881. doi:10.1016/j.lfs.2007.02.026 PubMedCrossRef

34.

Dallol A, Da Silva NF, Viacava P, Minna JD, Bieche I, Maher ER et al (2002) SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res 62:5874–5880PubMed

35.

Schmid BC, Rezniczek GA, Fabjani G, Yoneda T, Leodolter S, Zeillinger R (2007) The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells. Breast Cancer Res Treat 106:333–342. doi:10.1007/s10549-007-9504-0 PubMedCrossRef

36.

Zhao C, Yasui K, Lee CJ, Kurioka H, Hosokawa Y, Oka T et al (2003) Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 98:18–23. doi:10.1002/cncr.11482 PubMedCrossRef

37.

Woodfield GW, Horan AD, Chen Y, Weigel RJ (2007) TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling. Cancer Res 67:8439–8443. doi:10.1158/0008-5472.CAN-07-2293 PubMedCrossRef

38.

Martin MD, Matrisian LM (2007) The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 26:717–724. doi:10.1007/s10555-007-9089-4 PubMedCrossRef

39.

Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C et al (2003) Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3:589–601. doi:10.1016/S1535-6108(03)00133-8 PubMedCrossRef

40.

Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J (1999) The generation of endostatin is mediated by elastase. Cancer Res 59:6052–6056PubMed

41.

Dasse E, Bridoux L, Baranek T, Lambert E, Salesse S, Sowa ML et al (2007) Tissue inhibitor of metalloproteinase-1 promotes hematopoietic differentiation via caspase−3 upstream the MEKK1/MEK6/p38alpha pathway. Leukemia 21:595–603PubMed

42.

Wang T, Yamashita K, Iwata K, Hayakawa T (2002) Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways. Biochem Biophys Res Commun 296:201–205. doi:10.1016/S0006-291X(02)00741-6 PubMedCrossRef

43.

Jung KK, Liu XW, Chirco R, Fridman R, Kim HR (2006) Identification of CD63 as a tissue inhibitor of metalloproteinase−1 interacting cell surface protein. Embo J 25:3934–3942PubMedCrossRef

44.

Kopitz C, Gerg M, Bandapalli OR, Ister D, Pennington CJ, Hauser S et al (2007) Tissue inhibitor of metalloproteinases−1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res 67:8615–8623. doi:10.1158/0008-5472.CAN-07-0232 PubMedCrossRef

Title: TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro
Authors: Rebecca L. H. Bigelow
Briana J. Williams
Jennifer L. Carroll
Lisa K. Daves
James A. Cardelli
Publication date: 01-09-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0170-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Analysis of the effect of age on the prognosis of breast cancer

Molecular diagnosis of the Portuguese founder mutation BRCA2 c.156_157insAlu

Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial

Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors

Vitreo-retinal traction and anastrozole use

BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer